Thursday, 15 October 2026European Markets

NYRSTAR Stock Went Down By Over 27% In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of NYRSTAR (BEL 20: NYR.BR) slid by a staggering 27.49% in 21 sessions from €0.17 to €0.12 at 13:24 EST on Tuesday, after four consecutive sessions in a row of losses. BEL 20 is jumping 0.17% to €3,915.12, after four consecutive sessions in a row of losses.

NYRSTAR's last close was €0.13, 55.69% below its 52-week high of €0.29.

About NYRSTAR

Nyrstar NV engages in mining, smelting, and producing zinc, lead, and other base and precious metals primarily in Europe, Australia, Canada, and the United States. The company operates in Metals Processing and Mining segments. It offers zinc in concentrate from its mining operations; and refined market zinc products, including special high grade zinc, zinc galvanizing alloys, and zinc die-casting alloys for various applications and uses, such as construction and infrastructure, transport, industrial machinery, communications, electronics, and consumer products. The company also produces copper in concentrates and copper cathodes used in building construction, electrical and electronic products, transportation equipment, consumer products, and industrial machinery and equipment; and lead in concentrate primarily for the production of batteries. In addition, it offers gold and silver in concentrate and dore; indium and cadmium; and sulphuric acid for the production of fertilizers, fibers, paints, rubber, plastics, steel, detergents, and medicines. Nyrstar NV was founded in 2007 and is based in Zurich, Switzerland.

Earnings Per Share

As for profitability, NYRSTAR has a trailing twelve months EPS of €-7.066.

Volume

Today's last reported volume for NYRSTAR is 29004 which is 32.63% below its average volume of 42847.

Moving Average

NYRSTAR's worth is way below its 50-day moving average of €0.16 and way below its 200-day moving average of €0.20.

More news about NYRSTAR (NYR.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com